微芯生物(688321) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥119,751,736.11, representing a year-over-year increase of 28.44%[8] - The net profit attributable to shareholders for Q3 2022 was -¥22,922,857.19, with a year-to-date net profit of -¥42,211,182.77[8] - Total operating revenue for the first three quarters of 2022 reached CNY 335,672,990.64, an increase of 21.4% compared to CNY 276,545,965.86 in the same period of 2021[32] - The net loss attributable to shareholders of the parent company for Q3 2022 was CNY -42,211,182.77, compared to a net loss of CNY -24,254,905.09 in Q3 2021[39] - The company reported a total comprehensive loss of CNY -43,778,468.38 for Q3 2022, compared to a loss of CNY -24,254,905.09 in Q3 2021[39] - Basic and diluted earnings per share for Q3 2022 were both CNY -0.1037, compared to CNY -0.0591 in Q3 2021[39] Research and Development - Research and development expenses totaled ¥88,638,551.08 for Q3 2022, an increase of 42.21% compared to the same period last year[11] - R&D expenses accounted for 74.02% of operating revenue in Q3 2022, up by 7.17 percentage points year-over-year[11] - Research and development expenses increased to CNY 128,911,960.16 in Q3 2022, a rise of 40.9% from CNY 91,469,526.90 in Q3 2021[36] - The company continues to focus on independent R&D innovation, necessitating significant investment in R&D to advance ongoing projects[19] Assets and Liabilities - The total assets at the end of Q3 2022 were ¥2,741,364,643.65, reflecting a 44.71% increase from the end of the previous year[11] - Total current assets increased to ¥1,127,300,392.95 from ¥638,821,140.58 year-over-year[28] - Total assets as of September 30, 2022, are ¥2,741,364,643.65, up from ¥1,894,406,023.56 at the end of 2021[31] - The company's fixed assets increased to ¥783,713,505.03 from ¥534,769,585.14 year-over-year[31] - Total liabilities increased to ¥340,987,100.09 from ¥293,839,051.54 year-over-year[31] - Total liabilities amounted to CNY 1,109,267,404.86, significantly higher than CNY 476,792,465.34 from the previous year[32] - Total equity attributable to shareholders of the parent company was CNY 1,568,761,648.34, up from CNY 1,417,613,558.22 in the previous year[32] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥1,752,038.31, down by 96.89% compared to the previous year[11] - Operating cash inflows totaled approximately ¥368.20 million, slightly up from ¥363.99 million year-over-year[42] - Operating cash outflows increased to ¥366.45 million from ¥307.65 million, resulting in a net cash flow from operating activities of ¥1.75 million, down from ¥56.34 million[42] - Investment cash inflows decreased significantly to ¥259.02 million from ¥706.77 million, while investment cash outflows rose to ¥884.03 million from ¥723.60 million, leading to a net cash flow from investing activities of -¥625.02 million[42] - Financing cash inflows surged to ¥1.11 billion from ¥172.93 million, with net cash flow from financing activities reaching ¥858.59 million, compared to -¥12.32 million previously[44] - Cash and cash equivalents at the end of the period stood at ¥549.93 million, up from ¥298.12 million[44] - The total cash increase for the period was ¥249.77 million, compared to an increase of ¥26.56 million in the prior year[44] Shareholder Information - Total number of common shareholders at the end of the reporting period is 19,781[20] - The largest shareholder, BGI Group, holds 42,919,572 shares, representing 10.45% of total shares[20] - The second largest shareholder, Shenzhen Haiyue Men Biotechnology Development Co., Ltd., holds 22,936,008 shares, representing 5.58%[20] - The company has not engaged in margin trading or securities lending activities among its top shareholders[23] Government Subsidies and Other Income - The company reported a total of ¥3,910,157.23 in government subsidies recognized in Q3 2022[13] - Cash received from sales of goods and services in the first three quarters of 2022 was CNY 351,391,756.24, an increase from CNY 314,128,886.49 in the same period of 2021[40] Financial Expenses - The company’s financial expenses included interest expenses of CNY 10,533,938.08 in Q3 2022, compared to CNY 3,095,043.70 in Q3 2021[36] Employee Compensation and Tax Payments - The company reported a significant increase in employee compensation payments, totaling ¥191.66 million, compared to ¥148.38 million last year[42] - Tax payments decreased slightly to ¥20.70 million from ¥22.04 million[42] Foreign Exchange and Other Gains - The company experienced a foreign exchange gain of ¥14.45 million, contrasting with a loss of ¥0.64 million in the previous period[44]